Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancer - Top-Institutions - MDSpire

Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancer

  • By

  • Julien Taieb

  • Mehdi Karoui

  • September 8, 2025

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Gastrointestinal Oncology
    • Immunotherapy Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Cancer Immunotherapy
    • Molecular Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Gastrointestinal Cancers
    • Immuno-oncology

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Cancer Genetics
    • Immunotherapy

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Gastrointestinal Oncology

Original Source(s)

Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancer

  • by Julien Taieb, Mehdi Karoui

  • September 8, 2025

Related Content

Robotic-assisted colorectal surgery increases the adherence to enhanced recovery concepts

A Life-Extending Study for Colorectal Cancer Patients with Inoperable Liver Metastases

Physicians at Fox Chase Cancer Center have begun accepting patients for a new clinical trial looking at the effectiveness of a hepatic artery infusion (HAI) pump along with standard chemotherapy. Fox Chase is the only local hospital offering this trial, which is designed for patients with colorectal cancer that has spread to the liver and cannot be treated with surgery.

  • by

  • September 13, 2025

  • 3 min
Comparative Analysis of Thermal Ablation and Hepatectomy for Solitary Colorectal Liver Metastases up to 5 cm: Insights from a Multicenter Trial Emulation on Safety, Effectiveness, and Economic Viability